tbuckley/cabot-search huggingface dataset:
Alveolar soft-part sarcoma with lymph node metastasis in the rectum
Authors: Youming Xu, Huihua He, Qiuyun Yang, Wei Tan
Journal: Endoscopy (2025)

A 37-year-old woman was referred to our department because of prolonged abdominal pain and anemia. She underwent a colonoscopy, which revealed a 12-mm protuberance in the rectum ([Fig. 1] a). In addition, an MRI scan showed a 37-mm mass within the mesorectal envelope ([Fig. 1] b). Based on these clinical and imaging features, a rectal tumor and enlarged extramural lymph node were suspected. Subsequently, endoscopic ultrasonography (EUS) was performed and revealed two contrasting hypoechoic lesions ([Video 1]). The smaller, intraluminal lesion involved the 1st to 3rd layers of the rectum and had partially indistinct boundaries with the muscularis propria, which appeared slightly thickened ([Fig. 2]). The larger lesion showed minimal blood flow and was considered to be an enlarged lymph node. An EUS-guided biopsy was then conducted for evaluation. No biopsy was performed on the intrarectal lesion due to its small size. Microscopic examination indicated focal myofibroblast and small-vessel proliferation, consistent with a benign mesenchymal tumor. However, immunohistochemistry ruled out gastrointestinal stromal tumor, schwannoma, and leiomyoma. Unfortunately, cytology and liquid-based cytology tests detected malignant adenocarcinoma cells. Ultimately, the patient underwent Dixon surgery and lymphadenectomy. Metastases were observed in 3 of the 23 mesenteric lymph nodes, with the largest lesion measuring 3.5 cm in diameter. Radiotherapy was performed 1 week after surgery. Postoperative specimens gave positive results on ASPSCR1/TFE3 gene testing, with fusion of the ASPSCR1 and TFE3 genes, and on TFE3 (Xp11.2) gene testing, with evidence of TFE3 gene fragmentation ([Fig. 3]).
A novel nonslip short-length balloon catheter for endoscopic papillary large balloon dilation
Authors: Tadahisa Inoue, Rena Kitano, Tomoya Kitada, Kazumasa Sakamoto, Satoshi Kimoto, Jun Arai, Kiyoaki Ito
Journal: Endoscopy (2025)

Endoscopic papillary large balloon dilation (EPLBD) is an effective technique for removing large or stacked bile duct stones [1]. However, slippage during dilation is a common challenge, often prolonging procedures, necessitating multiple attempts, and increasing the risk of adverse events. This issue is more pronounced with larger EPLBD balloons compared to standard endoscopic papillary balloon dilation. Although longer balloons may reduce slippage, they can cause unnecessary dilation beyond the papilla and are challenging to use in cases where stones are located near the papilla. Additionally, maintaining an adequate distance between the endoscope and the papilla can be challenging during the procedure.
Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: interim analysis of a single-arm phase 2/3 study
Authors: Katia Alves, Karen Kotloff, R Scott McClelland, Alex Kouassi, Joyce S Plested, Raj Kalkeri, MingZhu Zhu, Shane Cloney-Clark, Zhaohui Cai, Katherine Smith, Muneer Kaba, Joy Nelson, E Adrianne Hammershaimb, Raburn M Mallory, Fernando Noriega
Journal: The Lancet Infectious Diseases (2025)
Endoscopic removal of an unexpected colon foreign body
Authors: Jingjing Lian, Aiping Xu, Tao Chen, Yuan Chu, Yan Tang, Yanli Ni, Meidong Xu
Journal: Endoscopy (2025)

A 48-year-old woman underwent a colonoscopy at our hospital for routine screening. During the procedure, a suspicious fistula was identified in the descending colon ([Fig. 1]), with a brown metallic foreign body visible at the fistula opening as the endoscope approached ([Fig. 2]). We grasped the exposed end of the foreign body with biopsy forceps and slowly pulled it into the intestinal lumen with great caution ([Video 1]). Finally, the foreign body was successfully removed without any active bleeding and it was confirmed to be an intrauterine device (IUD) ([Fig. 3]).
Endoscopic suture-based closure of an enterocutaneous fistula after one-anastomosis gastric bypass
Authors: Patrick Rebnegger, Antonia Gantschnigg, Michael Grechenig, Klaus Emmanuel, Josef Holzinger, Franz Singhartinger
Journal: Endoscopy (2025)

Gastrointestinal cutaneous fistulas are complex and challenging surgical conditions that occur predominantly postoperatively [1]. Effective treatment requires a multidisciplinary approach, with surgical revision carefully planned and typically considered after the failure of conservative treatments [2]. Endoscopic therapies, including clipping and vacuum therapy, along with newly developed endoscopic suture-based techniques, have shown promising results in closing fistulas without the high morbidity and mortality of surgical interventions [3] [4] [5].
A novel technique for precoagulation of blood vessels during saline-immersion colorectal endoscopic submucosal dissection: flushing forced method
Authors: Hiromitsu Ban, Tatsuma Nomura, Takashi Toyonaga
Journal: Endoscopy (2025)

Endoscopic visibility is maintained during saline-immersion endoscopic submucosal dissection (ESD), and this technique is widely used for management of colorectal and duodenal tumors. We previously proposed the F1–10 method for the precoagulation of vessels under gaseous conditions [1] [2]. However, under saline immersion, the same high frequency setting cannot stabilize the current, resulting in insufficient precoagulation. Recently, an endoscopic water irrigation pump (EIP2; Erbe Elektromedizin GmbH, Tübingen, Germany) was reported to remove bubbles generated during ESD under saline-immersion conditions [3]. Thus, to ensure precoagulation under saline-immersion conditions, we developed the "flushing forced method" using the EIP2.
Aspirin after completion of standard adjuvant therapy for colorectal cancer (ASCOLT): an international, multicentre, phase 3, randomised, double-blind, placebo-controlled trial
Authors: John W K Chia, Eva Segelov, Yanhong Deng, Gwo Fuang Ho, Wei Wang, Shuting Han, Atul Sharma, Kefeng Ding, Gong Chen, Mark G Jeffery, Chee Kian Tham, Joong Bae Ahn, Louise Nott, Robert Zielinski, Tsu-Yi Chao, Tom van Hagen, Po-Li Wei, Fiona Day, Shaesta Mehta, Thomas Yau, Jiewen Peng, Theresa M Hayes, Yong Li, Mihir Gandhi, Estelle M J Foo, Nabilah Rahman, Peter Rothwell, Raghib Ali, John Simes, Han Chong Toh
Journal: The Lancet. Gastroenterology & hepatology (2025)
Novel steerable-tip catheter successfully used for cannulation of a steeply angled pancreaticojejunostomy anastomotic stenosis
Authors: Haruka Toyonaga, Takuya Takayama, Tatsuya Nakagawa, Masataka Kano, Masahiro Orino, Hironao Matsumoto, Masaaki Shimatani
Journal: Endoscopy (2025)

Pancreaticojejunostomy anastomotic stenosis following pancreaticoduodenectomy is one of the most challenging issues an endoscopist can face. Its management often requires balloon enteroscopy-assisted endoscopic retrograde cholangiopancreatography (BE-ERCP); however, several obstacles can impede the successful completion of the procedure. These include difficulty in accessing the anastomosis owing to adhesions, challenges in identifying the anastomosis, and difficulty in selective pancreatic duct cannulation due to the anastomotic stenosis in combination with the steep angulation between the afferent limb and the pancreatic duct that is inherent to this surgical reconstruction ([Fig. 1]) [1] [2]. Various techniques have been reported to address these challenges [3], but achieving successful cannulation of the pancreaticojejunostomy remains difficult, occasionally necessitating endoscopic ultrasonography (EUS)-guided interventions. Recently, a newly developed steerable-tip catheter (KC226; Zeon Medical, Tokyo, Japan), with the tip composed of expanded polytetrafluoroethylene (ePTFE) that has a maximum bending angle of ±90° [4] [5], has become available, offering effective cannulation for pancreaticojejunostomy anastomotic stenosis with severe angulation ([Fig. 2]).
Definition and diagnostic criteria of clinical obesity
Authors: Francesco Rubino, David E Cummings, Robert H Eckel, Ricardo V Cohen, John P H Wilding, Wendy A Brown, Fatima Cody Stanford, Rachel L Batterham, I Sadaf Farooqi, Nathalie J Farpour-Lambert, Carel W le Roux, Naveed Sattar, Louise A Baur, Katherine M Morrison, Anoop Misra, Takashi Kadowaki, Kwang Wei Tham, Priya Sumithran, W Timothy Garvey, John P Kirwan, José-Manuel Fernández-Real, Barbara E Corkey, Hermann Toplak, Alexander Kokkinos, Robert F Kushner, Francesco Branca, Jonathan Valabhji, Matthias Blüher, Stefan R Bornstein, Harvey J Grill, Eric Ravussin, Edward Gregg, Noor B Al Busaidi, Nasreen F Alfaris, Ebaa Al Ozairi, Lena M S Carlsson, Karine Clément, Jean-Pierre Després, John B Dixon, Gauden Galea, Lee M Kaplan, Blandine Laferrère, Martine Laville, Soo Lim, Jesús R Luna Fuentes, Vicki M Mooney, Joseph Nadglowski, Agbo Urudinachi, Magdalena Olszanecka-Glinianowicz, An Pan, Francois Pattou, Philip R Schauer, Matthias H Tschöp, Maria T van der Merwe, Roberto Vettor, Geltrude Mingrone
Journal: The Lancet Diabetes & Endocrinology (2025)
Unlocking the power of empagliflozin: Rescuing inflammation in hyperglycaemia‐ exposed human cardiomyocytes through comprehensive multi‐level analysis
Authors: Rosaria Benedetti, Ugo Chianese, Chiara Papulino, Lucia Scisciola, Mirko Cortese, Pietro Formisano, Nunzio Del Gaudio, Serena Cabaro, Vittoria D'Esposito, Ada Pesapane, Mariarosaria Conte, Giuseppe Signoriello, Michelangela Barbieri, Lucia Altucci, Giuseppe Paolisso
Journal: European Journal of Heart Failure (2025)

Aims Hyperglycaemic conditions increase cardiac stress, a common phenomenon associated with inflammation, aging, and metabolic imbalance. Sodium–glucose cotransporter 2 inhibitors, a class of anti‐diabetic drugs, showed to improve cardiovascular functions although their mechanism of action has not yet been fully established. This study investigated the effects of empagliflozin on cardiomyocytes following high glucose exposure, specifically focusing on inflammatory and metabolic responses. Methods and results A three‐part strategy was formulated: (i) a meta‐analysis of selected randomized clinical trials was carried out to assess the anti‐inflammatory effects of empagliflozin in diabetic patients; (ii) the impact of empagliflozin on human cardiomyocyte AC16 cells exposed to normal (5 mM) and high (33 mM) glucose concentrations for 2 and 7 days was explored by evaluating gene expression and protein levels of pivotal markers associated with cardiac inflammation, stress, endoplasmic reticulum damage, and calcium modulation; (iii) in silico data from bioinformatic analyses were exploited to construct an interaction map delineating the potential mechanism of action of empagliflozin on cardiac tissue. Empagliflozin reversed high‐glucose mediated alterations at the transcriptional level, decreasing inflammatory, metabolic, and aging signatures. Specifically, in vitro experiments on human cardiomyocytes, meta‐analyses of clinical data on inflammatory biomarkers from diabetic peripheral blood samples, and sequencing of pathological human heart tissues, all support that empagliflozin exerts anti‐inflammatory effects both systemically and directly in cardiac tissue, on cardiomyocytes. Conclusion Our study provides insights based on robust mechanistic data for optimizing heart failure management and highlights the intricate interplay between diabetes, inflammation, aging, and cardiovascular health.
Metabolically activated and highly polyfunctional intratumoral VISTA+ regulatory B cells are associated with tumor recurrence in early-stage NSCLC
Authors: Domenico Lo Tartaro, Beatrice Aramini, Valentina Masciale, Nikolaos Paschalidis, Francesco Demetrio Lofaro, Anita Neroni, Rebecca Borella, Elena Santacroce, Alin Liviu Ciobanu, Anna Valeria Samarelli, Federica Boraldi, Daniela Quaglino, Alessandra Dubini, Michele Gaudio, Gloria Manzotti, Francesca Reggiani, Federica Torricelli, Alessia Ciarrocchi, Antonino Neri, Federica Bertolini, Massimo Dominici, Pier Luigi Filosso, Franco Stella, Lara Gibellini, Sara De Biasi, Andrea Cossarizza
Journal: Molecular Cancer (2025)

B cells have emerged as central players in the tumor microenvironment (TME) of non-small cell lung cancer (NSCLC). However, although there is clear evidence for their involvement in cancer immunity, scanty data exist on the characterization of B cell phenotypes, bioenergetic profiles and possible interactions with T cells in the context of NSCLC. In this study, using polychromatic flow cytometry, mass cytometry, and spatial transcriptomics we explored the intricate landscape of B cell phenotypes, bioenergetics, and their interaction with T cells in NSCLC. Our analysis revealed that TME contains diverse B cell clusters, including VISTA+ Bregs, with distinct metabolic and functional profiles. Target liquid chromatography-tandem mass spectrometry confirmed the expression of VISTA on B cells. VISTA+ Bregs displayed high metabolic demand and were able to produce different cytokines, including interleukin (IL)-10, transforming growth factor (TGF)-β, IL-6, tumor necrosis factor (TNF), and granulocyte–macrophage colony-stimulating factor (GM-CSF). Spatial analysis showed colocalization of B cells with CD4+/CD8+ T lymphocytes in TME. The computational analysis of intercellular communications that links ligands to target genes, performed by NicheNet, predicted B-T interactions via VISTA-PSGL-1 axis. Colocalization analyses revealed that PSGL-1 T cells and VISTA+ B cells are adjacent in the TME. Notably, tumor infiltrating CD8+ T cells expressing PSGL-1 exhibited enhanced metabolism and cytotoxicity. In NSCLC patients, prediction analysis performed by PENCIL revealed the presence of an association between PSGL-1+CD8+ T cells and VISTA+ Bregs with lung recurrence. Our findings suggest a potential interaction between Bregs and T cells through the VISTA-PSGL-1 axis, that could influence NSCLC recurrence.
Randomized clinical trial of a digital integrative medicine intervention among patients undergoing active cancer treatment
Authors: Jun J. Mao, Karolina Bryl, Erin F. Gillespie, Angela Green, Tony K. W. Hung, Raymond Baser, Katherine Panageas, Michael A. Postow, Bobby Daly
Journal: npj Digital Medicine (2025)

Exercise and mindfulness-based interventions have growing evidence for managing fatigue and comorbid symptoms; however, packaging them in a cohesive digital way for patients undergoing cancer treatment has not been evaluated. We conducted a randomized controlled trial to assess the impact of a 12 week digital integrative medicine program, Integrative Medicine at Home (IM@Home), versus enhanced usual care on fatigue severity (primary outcome), comorbid symptoms and acute healthcare utilization (secondary outcomes), in 200 patients with solid tumors experiencing fatigue during treatment. Fatigue severity decreased more in IM@Home than in the control (1.99 vs. 1.51 points; p = 0.04). IM@Home participants also had reduced symptom distress (p = 0.003), anxiety (p = 0.03), and depression (p = 0.02). Acute healthcare utilization was lower with IM@Home, with fewer emergency department visits (rate ratio 0.49; p = 0.04), hospitalizations (4% vs. 12.9%; p = 0.03), and shorter hospital stays (4.25 vs. 10 days; p < 0.001). These promising findings should be confirmed in phase III clinical trials. "Study registered at clinicaltrials.gov (NCT05053230) on 09-20-2021".
Growth Differentiation Factor-15 Predicts Major Bleeding in Cancer Patients
Authors: Cornelia Englisch, Stephan Nopp, Florian Moik, Daniel Steiner, Angelika M Starzer, Monika Fritzer-Szekeres, Matthias Preusser, Anna S Berghoff, Ingrid Pabinger, Cihan Ay
Journal: JACC CardioOncology (2025)

The hemostatic system is tightly interconnected with cancer. Research has focused predominantly on thrombotic complications, but less is known about bleeding and bleeding risk prediction. Growth differentiation factor (GDF)-15 has previously emerged as a prognostic biomarker for bleeding. The aim of this study was to investigate the association and predictive ability of GDF-15 for bleeding risk in patients with cancer. The CAT-BLED (Vienna Cancer, Thrombosis, and Bleeding) study is a prospective, observational cohort study including cancer patients initiating systemic anticancer therapies. Patients were followed for up to 2 years for thrombotic and bleeding events. The primary outcome was major bleeding. GDF-15 was measured at inclusion and at 3 and 6 months of follow-up. A total of 779 patients (48% women, median age 62 years, 15% on therapeutic anticoagulation) were included. During a median follow-up period of 18 months, 79 patients (10.1%) experienced major bleeding (12-month cumulative incidence 8.8%; 95% CI: 6.7-10.9). Higher GDF-15 levels were independently associated with increased major bleeding risk (adjusted subdistribution HR per doubling: 1.29; 95% CI: 1.04-1.59), and patients with levels greater than the cohort median (1,864 ng/L) had a significantly higher 12-month cumulative incidence (13.1% vs 4.6%; P < 0.001). This association remained robust in follow-up measurements at 3 and 6 months. GDF-15 showed moderate to good discrimination for predicting 6-month major bleeding risk (C statistic = 0.69; 95% CI: 0.60-0.77). GDF-15 was not associated with venous thromboembolism but was strongly associated with mortality (adjusted HR: 1.37; 95% CI: 1.25-1.50). GDF-15 levels predict major bleeding risk in cancer patients and are not associated with venous thromboembolism, making GDF-15 a particularly promising biomarker for bleeding risk prediction.
Effects of Systemic Anticancer Treatment on Cardiorespiratory Fitness
Authors: Sara H Johansen, Torbjørn Wisløff, Elisabeth Edvardsen, Sofie T Kollerud, Johanne S S Jensen, Ginika Agwu, Konstantina Matsoukas, Jessica M Scott, Tormod S Nilsen
Journal: JACC CardioOncology (2025)

Poor cardiorespiratory fitness (CRF) is associated with a higher symptom burden and an increased prevalence of long-term treatment-related cardiovascular disease risk factors in cancer survivors. However, the magnitude of systemic therapy-related CRF impairment remains unclear. The aim of this study was to evaluate the effects of systemic anticancer treatment on CRF and identify physiological determinants underpinning CRF impairment. A systematic literature search was performed in PubMed, Embase, CINAHL, SPORTDiscus, and the Cochrane Library. The primary endpoint was the change in CRF, measured by peak oxygen consumption (Vo2peak), from before to after systemic treatment. Secondary endpoints included post-treatment differences in Vo2peak between cancer survivors and noncancer control subjects, along with physiological determinants of Vo2peak. Two meta-regressions were conducted to examine the association between CRF and cardiac output and arteriovenous oxygen difference. A total of 44 studies were included, comprising 27 prospective trials (61%; n = 1,234 cancer survivors, median age 52.4 years) and 17 cross-sectional studies (39%; n = 1,372 cancer survivors, median age 54.0 years; n = 1,923 noncancer control subjects, median age 56.0 years). Systemic anticancer treatment was associated with a significant decrease in Vo2peak (weighted mean difference -2.13 mL·kg-1·min-1; 95% CI: -2.76 to -1.50 mL·kg-1·min-1). No significant differences were observed between patient subgroups (esophagogastric, breast, and colon or rectal cancers). At a median follow-up of 2 years (range: 6 weeks to 12 years) post-therapy, cancer survivors had a significantly lower Vo2peak (weighted mean difference -6.39 mL·kg-1·min-1; 95% CI: -7.60 to -5.18 mL·kg-1·min-1) compared with noncancer control subjects. Reduced arteriovenous oxygen difference was associated with lower Vo2peak (β = 2.55; 95% CI: 2.05-3.06; P < 0.001). Systemic anticancer treatment leads to substantial and sustained impairments in CRF.
The Association of Malignancy With Stroke and Bleeding in Atrial Fibrillation
Authors: Malak El-Rayes, Mohamed Adam, Jiming Fang, Xuesong Wang, Irene Jeong, Peter C Austin, Andrew C T Ha, Michael G Fradley, Thomas A Boyle, Eitan Amir, Paaladinesh Thavendiranathan, Husam Abdel-Qadir
Journal: JACC CardioOncology (2025)

It is undetermined if malignancy independently increases stroke risk in atrial fibrillation (AF). This study sought to determine the association of malignancy with stroke and bleeding in AF. Population-based cohort study using administrative datasets of people aged ≥66 years with newly diagnosed AF. People diagnosed with malignancy within 5 years before AF diagnosis were matched to cancer-free control subjects on age, sex, AF diagnosis details, CHA2DS2-VASc score, and ATRIA bleeding score. Outcomes included hospitalizations for stroke and hospitalization/emergency visits for bleeding. Cause-specific regression was used to determine the HR for malignancy after adjusting for time-varying anticoagulation status. Analyses were repeated for specific subgroups of cancer patients (with matched control subjects). Among 199,710 AF patients, 24,991 (12.5%) people had prior malignancy. Malignancy was associated with more inpatient diagnoses of AF (vs outpatient) and less anticoagulation. We matched 43,802 people with AF (21,901 with malignancy, mean age 78.1 years; 59.5% male). After adjusting for anticoagulation status, malignancy had a similar hazard of stroke (HR: 1.01; 95% CI: 0.88-1.15) but higher hazard of bleeding (HR: 1.45; 95% CI: 1.37-1.53) compared with cancer-free control subjects in the matched sample. Analyses of cancer subgroups with comparison to matched control subjects mostly showed consistent results, except for: 1) increased hazard of stroke in lung cancer; and 2) lack of increased bleeding hazard in breast cancer and lymphoma. People with AF and malignancy generally had similar hazards of stroke but higher hazards of bleeding compared with cancer-free control subjects, suggesting that malignancy should not lower the threshold for anticoagulation in AF.
Transcatheter edge‐to‐edge repair in severe mitral regurgitation following acute myocardial infarction – aetiology‐based analysis
Authors: Dan Haberman, Rodrigo Estévez‐Loureiro, Andrew Czarnecki, Francesco Melillo, Marianna Adamo, Pedro Villablanca, Doron Sudarsky, Fabien Praz, Leor Perl, Xavier Freixa, Andrea Scotti, Paul Fefer, Konstantinos Spargias, Neil Fam, Lisa Manevich, Giulia Masiero, Luis Nombela‐Franco, Isaac Pascual, Gabriele Crimi, Vlasis Ninios, Ronen Beeri, Tomas Benito‐Gonzalez, Dabit Arzamendi, Estefanıa Fernández‐Peregrina, Francesco Giannini, Antonio Mangieri, Lion Poles, Jacob George, Julio Cesar Echarte Morales, Berenice Caneiro‐Queija, Paolo Denti, Davide Schiavi, Azeem Latib, Michael Chrissoheris, Haim Danenberg, Giuseppe Tarantini, Danny Dvir, Francesco Maisano, Maurizio Taramasso, Mony Shuvy
Journal: European Journal of Heart Failure (2025)
Diagnostic models to differentiate Takotsubo syndrome from acute coronary syndrome: A systematic review and meta‐analysis
Authors: Carlos Diaz‐Arocutipa, Adrian V. Hernandez, Cesar Joel Benites‐Moya, Norma Nicole Gamarra‐Valverde, Rafael Yrivarren‐Cespedes, Javier Torres‐Valencia, Lourdes Vicent
Journal: European Journal of Heart Failure (2025)
Comparative effectiveness of acupoint stimulation for preventing postoperative nausea and vomiting after general anesthesia: A network meta-analysis of randomized trials
Authors: Ting Zhou, Huaijin Hou, Zhuoma Cairen, Yun Wang, Peng Wang, Long Ge, Macuo Wa, Senbing Zhang, Ziqing Xu, Feng Tang, Caihong Wang, Rongxin Liu, Deyan Li, Jianjun Xue
Journal: International Journal of Surgery (2024)